¼¼°èÀÇ ±âÃÊ Àν¶¸° ½ÃÀå
Basal Insulin
»óǰÄÚµå : 1798352
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 179 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ±âÃÊ Àν¶¸° ½ÃÀåÀº 2030³â±îÁö 3¾ï 2,220¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 2¾ï 6,550¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ±âÃÊ Àν¶¸° ½ÃÀåÀº 2030³â¿¡´Â 3¾ï 2,220¸¸ ´Þ·¯¿¡ ´ÞÇϸç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 3.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ¶õÅõ½º Àν¶¸°Àº CAGR 2.3%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 1¾ï 190¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Levemir Insulin ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 4.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 7,230¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¾î Áß±¹Àº CAGR 5.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ ±âÃÊ Àν¶¸° ½ÃÀåÀº 2024³â¿¡ 7,230¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀ» 5.9%·Î, 2030³â±îÁö 6,310¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 1.4%¿Í 2.5%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ±âÃÊ Àν¶¸° ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Ä¡·á ÆÐ·¯´ÙÀÓÀÇ º¯È­´Â ´ç´¢º´ Ä¡·á¿¡¼­ ±âÃÊ Àν¶¸° »ç¿ë¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

´ç´¢º´ Ä¡·áÀÇ ÆÐ·¯´ÙÀÓÀÌ Å©°Ô º¯È­Çϰí ÀÖÀ¸¸ç, ±× Áß ±âÃÊ Àν¶¸°Àº Áß½ÉÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ±âÃÊ Àν¶¸°Àº Àå±â°£ ÁßÁ¤ÀûÀ¸·Î Àν¶¸°À» ºÐºñÇϵµ·Ï ¼³°èµÇ¾î ü³» ÀÚ¿¬ Àν¶¸° ºÐºñ¸¦ ¸ð¹æÇÏ¿© Á¦ 1Çü ¹× 2Çü ´ç´¢º´ÀÇ Ç÷´ç Á¶ÀýÀ» µ½½À´Ï´Ù. GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦, SGLT2 ¾ïÁ¦Á¦ µî »õ·Î¿î Ä¡·áÁ¦°¡ ÁÖ¸ñ¹Þ°í ÀÖÁö¸¸, ±âÃÊ Àν¶¸°Àº ƯÈ÷ °æ±¸¿ë Ç×´ç´¢º´Á¦¸¸À¸·Î´Â ¸ñǥġ¸¦ ´Þ¼ºÇÒ ¼ö ¾ø´Â ȯÀÚµéÀÇ Ç÷´ç °ü¸®ÀÇ ÇÙ½ÉÀ¸·Î ³²¾Æ ÀÖ½À´Ï´Ù. ÀÓ»ó ÇöÀå¿¡¼­´Â °íÇ÷´ç Àå±âÈ­¿¡ µû¸¥ ÇÕº´ÁõÀ» ¿¹¹æÇϱâ À§ÇØ ±âÃÊ Àν¶¸°ÀÇ Á¶±â Åõ¿©¸¦ Áß¿ä½ÃÇÏ´Â Àǻ簡 ´Ã°í ÀÖ½À´Ï´Ù. Àν¶¸°±Û¶óÁø, Àν¶¸°µ¥Å×¹Ð, Àν¶¸°µ¥±Û·çµ¦°ú °°Àº ÃֽбâÃÊ Àν¶¸° À¯»çü´Â º¸´Ù ¿¹Ãø °¡´ÉÇÑ ¾àµ¿ÇÐÀ» ³ªÅ¸³»¸ç, ¾ß°£ ÀúÇ÷´ç À§ÇèÀ» °¨¼Ò½Ã۰í, 1ÀÏ 1ȸ Åõ¿©·Î ¼øÀÀµµ¸¦ °³¼±ÇÕ´Ï´Ù. ¶ÇÇÑ ´ç´¢º´ÀÌ ÁøÇ༺ ÁúȯÀ̶ó´Â ÀνÄÀÌ È®»êµÇ¸é¼­ Ä¡·á ¸ñÇ¥°¡ °³º°È­µÇ¾ú°í, ±âÃÊ Àν¶¸°Àº ȯÀÚº° ¸ÂÃã½Ä º´¿ë ¿ä¹ýÀÇ ÀϺηΠÀÚÁÖ Æ÷ÇԵǾú½À´Ï´Ù. Àü ¼¼°è¿¡¼­ 2Çü ´ç´¢º´ Áõ°¡, ƯÈ÷ °í·ÉÈ­ ¹× ÁÂ½Ä »ýȰ½À°üÀ» °¡Áø »ç¶÷µéÀÇ ºÎ´ã Áõ°¡´Â Àå±âÀûÀÎ ´ë»ç Á¶ÀýÀ» À§ÇÑ ´Ù°¢ÀûÀÎ Á¢±ÙÀÇ ÀÏȯÀ¸·Î ±âÃÊ Àν¶¸° Ä¡·á¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¼ö¿ä¸¦ °­È­½Ã۰í ÀÖ½À´Ï´Ù.

Á¦Çü°ú Àü´Þ ½Ã½ºÅÛÀÇ ¹ßÀüÀÌ ±âÃÊ Àν¶¸°ÀÇ Ã¤ÅÃÀ» ÃËÁøÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

Á¦Çü °úÇаú Àν¶¸° Àü´Þ ½Ã½ºÅÛÀÇ ±â¼úÀû ¹ßÀüÀº ´Ù¾çÇÑ È¯ÀÚ Áý´Ü¿¡¼­ ±âÃÊ Àν¶¸°ÀÇ Ã¤Åðú »ç¿ë ÆíÀǼºÀ» Å©°Ô Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. Â÷¼¼´ë ±âÃÊ Àν¶¸° À¯»çü´Â Ç÷´ç º¯µ¿¼ºÀ» ÃÖ¼ÒÈ­Çϸ鼭 24½Ã°£ ÀÌ»ó Àå½Ã°£ Ç÷´ç Á¶ÀýÀÌ °¡´ÉÇÑ ÃÊÀå½Ã°£ ÀÛ¿ë ÇÁ·ÎÆÄÀÏÀ» À§ÇØ ¼³°èµÇ¾ú½À´Ï´Ù. ÀÌ´Â ºÒ±ÔÄ¢ÇÑ ½ºÄÉÁÙÀ» °¡Áø ȯÀÚ³ª ¾ö°ÝÇÑ Åõ¾à ŸÀֿ̹¡ ¾î·Á¿òÀ» °Þ´Â ȯÀڵ鿡°Ô ƯÈ÷ µµ¿òÀÌ µÇ´Â °ÍÀ¸·Î ÀÔÁõµÇ¾ú½À´Ï´Ù. Á¦Á¦ÀÇ ¾ÈÁ¤¼ºÀÌ Çâ»óµÇ¾î ÁÖ»ç ºÎÀ§ÀÇ ÆíÂ÷°¡ ÁÙ¾îµç °Íµµ º¸´Ù ¾ÈÁ¤ÀûÀÎ Ä¡·á °á°ú¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. Àü´Þ Ãø¸é¿¡¼­´Â »ç¿ëÀÚ Ä£È­ÀûÀÎ Àν¶¸° Ææ°ú µðÁöÅÐ ÁÖ»ç ÃßÀû ÅøÀÇ µîÀåÀ¸·Î Àν¶¸° Åõ¿©°¡ º¸´Ù Ä£¼÷ÇØÁ® »õ·Î Áø´Ü¹ÞÀº ȯÀڵ鿡°Ô Àν¶¸° Åõ¿©¿¡ ´ëÇÑ °ÅºÎ°¨ÀÌ ÁÙ¾îµé°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀº Á¾Á¾ Ä¡·á °­È­ Áö¿¬°ú °ü·ÃµÈ Àν¶¸° Åõ¿© ½ÃÀÛ¿¡ ´ëÇÑ ÀÎÁöÀû, ½É¸®Àû À庮À» ¿ÏÈ­Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² ¸ð¹ÙÀÏ °Ç°­ ¿ëµµ°ú Æ÷µµ´ç ¸ð´ÏÅ͸µ ±â¼úÀº ±âÃÊ Àν¶¸° Åõ¿©¿Í ½Ç½Ã°£ µ¥ÀÌÅÍ ÀλçÀÌÆ®ÀÇ ±ä¹ÐÇÑ ÅëÇÕÀ» Áö¿øÇÏ¿© ȯÀÚ¿Í ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ º¸´Ù Á¤º¸¿¡ ÀÔ°¢ÇÑ Ä¡·á Á¶Á¤À» ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ±âÃÊ Àν¶¸° ¹ÙÀÌ¿À½Ã¹Ð·¯ Á¦Ç°µµ ½ÃÀå¿¡ Ãâ½ÃµÇ¾î ǰÁú°ú È¿´ÉÀ» ÀúÇϽÃŰÁö ¾ÊÀ¸¸é¼­µµ ºñ¿ë È¿À²ÀûÀÎ ´ë¾ÈÀ» Á¦°øÇÔÀ¸·Î½á ¼±Áø±¹°ú ½ÅÈï ±¹°¡ ¸ðµÎ¿¡¼­ ÀÇ·á ½Ã½ºÅÛ Á¢±Ù¼ºÀ» È®´ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. º£ÀÌÁ÷ Àν¶¸°Àº Á¦Ç° µðÀÚÀΰú »ç¿ëÀÚ °æÇè Ãø¸é¿¡¼­ ´õ È¿°úÀûÀÏ »Ó¸¸ ¾Æ´Ï¶ó Á¡Á¡ ´õ ¸¹Àº Àü ¼¼°è ´ç´¢º´ ȯÀڵ鿡°Ô ´õ Ä£±ÙÇÏ°Ô ´Ù°¡°¥ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

ÀÇ·á Á¤Ã¥, ½ÃÀå Á¢±Ù¼º, ȯÀÚ ±³À°Àº ¼¼°è ±âÃÊ Àν¶¸° ½ÃÀåÀ» ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?

ÀÇ·á Á¤Ã¥ °³Çõ, »óȯ ¸ÞÄ¿´ÏÁò, ȯÀÚ ±³À°¿¡ ´ëÇÑ ³ë·ÂÀº Àü ¼¼°è¿¡¼­ ±âÃÊ Àν¶¸° Ä¡·á Á¢±Ù¼º°ú ¼øÀÀµµ¸¦ Çü¼ºÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¸¹Àº °í¼Òµæ ±¹°¡¿¡¼­´Â °æ±¸¿ë ¾à¹°·Î ºÒÃæºÐÇÑ 2Çü ´ç´¢º´ÀÇ 1Â÷ ¼±ÅÃÀû ÁÖ»ç ¿ä¹ýÀ¸·Î Áö¼ÓÇü ±âÃÊ Àν¶¸° Á¦Á¦ÀÇ »ç¿ëÀ» ÁöÁöÇÏ´Â º¸Çè Àû¿ë ¹× ±¹°¡ ÀÇ·á °èȹÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ´ç´¢º´ ȯÀÚÀÇ °æÁ¦Àû ºÎ´ãÀ» ÁÙÀ̱â À§ÇÑ Á¤Ã¥À¸·Î ÀÎÇØ À¯»çÇÑ Ä¡·á È¿°ú¸¦ ´õ ³·Àº ºñ¿ëÀ¸·Î Á¦°øÇÏ´Â ¹ÙÀÌ¿À½Ã¹Ð·¯ Àν¶¸° ¾Æ³¯·Î±×ÀÇ º¸±ÞÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª Àú¼Òµæ ȯ°æ¿¡¼­´Â °æÁ¦ÀûÀÎ ¹®Á¦¿Í Á¦ÇÑµÈ ÀÇ·á ÀÎÇÁ¶ó·Î ÀÎÇØ Á¢±Ù¼ºÀÌ ¿©ÀüÈ÷ ¹®Á¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ¼¼°è º¸°Ç±â±¸¿Í ºñ¿µ¸®´ÜüµéÀº °¡°Ý Çù»óÀ» ÅëÇØ Àν¶¸° °ø±Þ¸ÁÀ» Áö¿øÇÏ¿© Àν¶¸°À» ÃæºÐÈ÷ °ø±Þ¹ÞÁö ¸øÇÏ´Â »ç¶÷µé¿¡°Ô Àν¶¸°ÀÌ Àü´ÞµÇµµ·Ï ÇÔÀ¸·Î½á ÀÌ °ÝÂ÷¸¦ ÇØ¼ÒÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ 2Çü ´ç´¢º´ ȯÀÚµéÀº Áֻ糪 ÀúÇ÷´ç, Ä¡·á ½ÇÆÐ¿¡ ´ëÇÑ µÎ·Á¿ò ¶§¹®¿¡ Àν¶¸° Åõ¿©¸¦ ´Ê°Ô ½ÃÀÛÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ´ç´¢º´ ±³À°ÀÚÀÇ Á¤È®ÇÑ Á¤º¸¿Í Áö¿øÀ¸·Î ȯÀڵ鿡°Ô ÈûÀ» ½Ç¾îÁÖ´Â °ÍÀÌ Á¶±â µµÀÔ°ú ¼øÀÀµµ Çâ»óÀÇ ÇÙ½ÉÀÔ´Ï´Ù. °¢±¹ÀÌ µðÁöÅÐ Çコ ÅøÀ» °øÁߺ¸°Ç Àü·«¿¡ ÅëÇÕÇÔ¿¡ µû¶ó °¡»ó Áø·á¿Í ¿ø°ÝÀǷḦ Ȱ¿ëÇÏ¿© Á¡ÁøÀû Åõ¿©¸¦ ÅëÇØ ȯÀÚ¸¦ ÁöµµÇϰí Àå±âÀûÀÎ °á°ú¸¦ ¸ð´ÏÅ͸µÇÔÀ¸·Î½á Àν¶¸° »ç¿ë¿¡ ´ëÇÑ ½Å·Ú¸¦ ³ôÀ̰í Áý´Ü ¼öÁØ¿¡¼­ Àü¹ÝÀûÀÎ ´ç´¢º´ °ü¸®¸¦ °­È­ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. °­È­µÇ°í ÀÖ½À´Ï´Ù.

±âÃÊ Àν¶¸° ¼¼°è ½ÃÀå ¼ºÀå ¿øµ¿·ÂÀº?

¼¼°è ±âÃÊ Àν¶¸° ½ÃÀåÀÇ ¼ºÀåÀº ¿ªÇÐ µ¿Çâ, ±â¼ú ¹ßÀü, Àü·«Àû ½ÃÀå °³¹ßÀÇ Á¶ÇÕ¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ´ç´¢º´, ƯÈ÷ 2Çü ´ç´¢º´ÀÇ Àü ¼¼°è À¯º´·ü Áõ°¡´Â ¼ö¿ä¸¦ ÃËÁøÇÏ´Â °¡Àå µÎµå·¯Áø ¿äÀÎÀ̸ç, ºñ¸¸, Á½ĻýȰ, °í·ÉÈ­ µî »ýȰ½À°ü ¿äÀÎÀÌ ÀÌ·¯ÇÑ ±ÞÁõ¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÎ´ã Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ ÀÇ·á ½Ã½ºÅÛÀº Àν¶¸° ¿ä¹ý, ƯÈ÷ Ç÷´ç ¸ñǥġ ´Þ¼º ¹× À¯Áö¿¡ È¿°ú°¡ ÀÔÁõµÈ ±âÃÊ Àν¶¸°ÀÇ Á¶±â ½ÃÀÛ°ú Àå±âÀûÀÎ ÃÖÀûÈ­¸¦ ¿ì¼±½ÃÇϰí ÀÖ½À´Ï´Ù. º¸´Ù ÆòźÇÑ ÀÛ¿ë ÇÁ·ÎÆÄÀϰú ¿¬ÀåµÈ Áö¼Ó½Ã°£ µî ¾à·ÂÇÐÀû Ư¼ºÀÌ °³¼±µÈ »õ·Î¿î Àν¶¸° À¯»çüÀÇ Ãâ½Ã´Â º¸´Ù Æí¸®Çϰí È¿°úÀûÀÎ ¼±ÅÃÀ» ¿øÇÏ´Â ÀÓ»óÀÇ¿Í È¯ÀÚ ¸ðµÎ¸¦ ¸Å·á½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹ÙÀÌ¿À½Ã¹Ð·¯ ±â¹Ý Àν¶¸°ÀÇ °¡¿ë¼ºÀÌ ³ô¾ÆÁü¿¡ µû¶ó Ä¡·á Á¢±Ù¼ºÀÌ È®´ëµÇ´Â ÇÑÆí, Á¦Á¶¾÷ü °£ °æÀïÀÌ Ä¡¿­ÇØÁ® º¸´Ù ÇÕ¸®ÀûÀÎ °¡°Ý°ú Æø³ÐÀº ½ÃÀå ħÅõ°¡ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. Á¦¾à»ç¿Í µðÁöÅÐ Çコ Ç÷§ÆûÀÇ Á¦ÈÞµµ ȯÀÚÀÇ ¼øÀÀµµ¿Í ½ÇÁ¦ ÀÓ»ó °á°ú ÃßÀûÀ» Áö¿øÇÏ´Â ÅëÇÕ ´ç´¢º´ °ü¸® »ýŰ踦 ±¸ÃàÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ µµ½ÃÈ­¿Í ÇコÄɾî ÅõÀÚ·Î ÀÎÇØ ȯÀÚ Á¢±Ù¼ºÀÌ È®´ëµÇ°í ÀÖ´Â ½ÅÈï ½ÃÀå¿¡¼­ÀÇ Áø´ÜÀ² Áõ°¡µµ ¼ºÀåÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÃËÁø¿äÀÎÀ» Á¾ÇÕÇÏ¸é ±âÃÊ Àν¶¸° ½ÃÀåÀº °ß°íÇϰí Áö¼Ó°¡´ÉÇÑ ±Ëµµ¿¡ ÁøÀÔÇϰí ÀÖÀ¸¸ç, ´çºÐ°£ ¼¼°è ´ç´¢º´ Ä¡·á¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ³²À» °ÍÀÌ È®½ÇÇÕ´Ï´Ù.

ºÎ¹®

Á¦Ç°(Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin, Basaglar Insulin)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø·Î ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Basal Insulin Market to Reach US$322.2 Million by 2030

The global market for Basal Insulin estimated at US$265.5 Million in the year 2024, is expected to reach US$322.2 Million by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Lantus Insulin, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$101.9 Million by the end of the analysis period. Growth in the Levemir Insulin segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$72.3 Million While China is Forecast to Grow at 5.9% CAGR

The Basal Insulin market in the U.S. is estimated at US$72.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$63.1 Million by the year 2030 trailing a CAGR of 5.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Basal Insulin Market - Key Trends & Drivers Summarized

How Are Shifting Treatment Paradigms Influencing the Use of Basal Insulin in Diabetes Care?

The landscape of diabetes management has been undergoing significant transformation, and basal insulin continues to play a central role in these evolving treatment paradigms. Designed to provide a steady release of insulin over a prolonged period, basal insulin supports glucose control in both type 1 and type 2 diabetes by mimicking the body’s natural background insulin secretion. While newer therapies such as GLP-1 receptor agonists and SGLT2 inhibitors are gaining attention, basal insulin remains a cornerstone in glycemic management, especially for patients who fail to achieve targets with oral antidiabetic drugs alone. In clinical practice, physicians increasingly emphasize early initiation of basal insulin to prevent complications related to prolonged hyperglycemia. Modern basal insulin analogs like insulin glargine, insulin detemir, and insulin degludec offer more predictable pharmacokinetics, reduced risk of nocturnal hypoglycemia, and improved adherence due to once-daily dosing. Additionally, the recognition of diabetes as a progressive condition has shifted treatment goals toward individualized care, where basal insulin is frequently integrated as part of combination regimens tailored to patient-specific needs. The growing burden of type 2 diabetes worldwide, particularly in aging populations and those with sedentary lifestyles, reinforces the ongoing demand for basal insulin therapy as part of a multifaceted approach to long-term metabolic control.

Why Are Advancements in Formulation and Delivery Systems Enhancing Basal Insulin Adoption?

Technological progress in formulation science and insulin delivery systems is significantly enhancing the adoption and usability of basal insulin across diverse patient populations. Next-generation basal insulin analogs are being engineered for ultra-long action profiles, offering extended glucose control beyond 24 hours with minimal fluctuations in blood sugar levels. This has proven particularly beneficial for patients with irregular schedules or those who face challenges with rigid medication timing. Improved formulation stability and lower injection site variability are also contributing to more consistent therapeutic outcomes. On the delivery front, the rise of user-friendly insulin pens and digital injection tracking tools is making insulin administration more accessible and less intimidating for newly diagnosed patients. These innovations reduce the cognitive and psychological barriers to insulin initiation, a factor often associated with delayed treatment intensification. In parallel, mobile health applications and glucose monitoring technologies now support tighter integration of basal insulin dosing with real-time data insights, helping patients and healthcare providers make more informed treatment adjustments. Biosimilar versions of basal insulin have also entered the market, offering cost-effective alternatives without compromising quality or efficacy, thus expanding access in both developed and emerging healthcare systems. These ongoing innovations in both product design and user experience are making basal insulin not only more effective but also more approachable for the growing global diabetic population.

How Are Health Policy, Market Access, and Patient Education Shaping the Global Basal Insulin Market?

Health policy reforms, reimbursement mechanisms, and patient education efforts are playing critical roles in shaping access and adherence to basal insulin therapies globally. In many high-income countries, insurance coverage and national health plans increasingly support the use of long-acting basal insulins as first-line injectable therapy for type 2 diabetes when oral medications are insufficient. Policies aimed at reducing the economic burden of diabetes are facilitating wider adoption of biosimilar insulin analogs, which offer similar therapeutic benefits at a lower cost. In lower-income settings, however, access remains a challenge due to affordability issues and limited healthcare infrastructure. Global health organizations and non-profits are working to close this gap by negotiating pricing agreements and providing supply chain support to ensure that insulin reaches underserved populations. Alongside access efforts, education initiatives are gaining traction to address insulin hesitancy, particularly among type 2 diabetes patients who often delay insulin initiation due to fears of injections, hypoglycemia, or perceived treatment failure. Empowering patients with accurate information and support from diabetes educators is key to improving early adoption and adherence. As countries integrate digital health tools into their public health strategies, virtual care and telemedicine are being leveraged to guide patients through basal insulin titration and monitor long-term outcomes, thereby boosting confidence in insulin use and enhancing overall diabetes control at a population level.

What Is Driving the Growth of the Global Basal Insulin Market?

The growth in the global basal insulin market is being driven by a combination of epidemiological trends, technological advancements, and strategic market developments. The rising global prevalence of diabetes, particularly type 2 diabetes, is the most prominent factor fueling demand, with lifestyle factors such as obesity, sedentary behavior, and aging populations contributing significantly to this surge. In response to this growing burden, healthcare systems are prioritizing the early initiation and long-term optimization of insulin therapy, especially basal insulin, due to its proven efficacy in achieving and maintaining glycemic targets. The launch of novel insulin analogs with improved pharmacodynamic properties, such as flatter action profiles and longer durations, is attracting both clinicians and patients seeking more convenient and effective options. In addition, the increasing availability of biosimilar basal insulins is expanding treatment access while intensifying competition among manufacturers, leading to better affordability and broader market penetration. Partnerships between pharmaceutical companies and digital health platforms are also creating integrated diabetes management ecosystems that support patient adherence and real-world outcome tracking. Growth is further supported by expanding diagnosis rates in emerging markets, where urbanization and healthcare investment are increasing patient reach. Altogether, these drivers are establishing a robust and sustainable trajectory for the basal insulin market, ensuring it remains a vital component of global diabetes care for the foreseeable future.

SCOPE OF STUDY:

The report analyzes the Basal Insulin market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin, Basaglar Insulin)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â